“It wasn’t until later that I discovered what it means to recognize oneself as Afro,” said Castorela, who subsequently confirmed her African ancestry. “We are a diverse community which, perhaps due to discrimination, doesn’t identify as such.”
So are they glad they get another shot at the Panthers?“It doesn’t matter. You’re competing for a Stanley Cup,” said Perry, a Cup champion at age 22 with Anaheim in 2007, and now going into his fifth Final in six seasons while still seeking another title.
“I mean we know what they’re about. We played them seven times and they’re a good team,” Draisaitl said. “We’re really a good team as well. Obviously it’s nice to get a shot at, you know, getting some revenge, but a long ways from that.”FORT LAUDERDALE, Fla. (AP) — The Florida Panthers don’t play hockey every day. It only seems like that’s the case.When the Panthers take the ice for Game 1 of the Stanley Cup Final in Edmonton on Wednesday night, it will be the team’s 309th game over the past three seasons and one that ties the NHL record for most games in a three-year span. And that, obviously, means they’ll break the record in Game 2 on Friday.
There is no downside to making the Stanley Cup Final in three consecutive seasons, though there has been one unintended consequence — the Panthers are playing a ton of hockey. It’s simultaneously tiring and exhilarating.“We will have more energy for this series than any of the three prior,” coach Paul Maurice said. “And I’m sure it’s true of Edmonton as well. But the regular season was more of a grind for us this year than either of the two previous. And then in each round, it seemed a bigger build to excitement just because the light is at the end of the tunnel. There are no more than seven games left to this season, no matter what. So, you will see a new energy source from both teams in this series.”
Dallas (1997-98 through 1999-2000) and Detroit (2006-07 through 2008-09) hold the record for most games in a three-year span with 309; the
was their 308th in three seasons, putting them on the brink of passing those clubs.and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.
After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.The effect was evident in women, but not statistically significant in men. The study couldn’t explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.How can the U.S. solve its growing maternal mortality crisis? Health experts say one way is to look to other countries.